Learn how Monolith helps you facilitate the rational design of your PROTACs.
Have a question about Monolith?
Contact SpecialistSee more related content
Are you building an effective protein degrader? 4 questions to ask yourself to find out
Protein degraders are getting a lot of attention for being a new and promising modality to treat diseases such as cancer or Alzheimer’s disease. Rather than inhibiting the function of a protein,...
25:40Are you struggling to tame your mischievous membrane proteins? Find out how NanoTemper can help you to characterize even the most challenging membrane protein samples. You will learn how Prometheus ca
6 protein degradation conferences in 2021 you can’t afford to miss
Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation (TPD). Many transcription factors, scaffold proteins,...
59:35Bifunctional degrader molecules (also known as PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases. The formation of a ternary complex between PROTAC, ligase, and the protein of inte
Thermophoretic analysis of ligand-specific conformational states of the inhibitory glycine receptor embedded in copolymer nanodiscs
Can bioanalytical tools solve your neurodegenerative disease research challenges? 4 questions to ask yourself
Despite extensive efforts, neurodegenerative diseases (ND) continue to feel like a pharmaceutical frontier. We have yet to see any effective drugs for conditions such as Alzheimer’s, Parkinson’s,...
Phospholipid membrane fluidity alters ligand binding activity of a G protein-coupled receptor by shifting the conformational equilibrium
Characterize the true nature of intrinsically disordered proteins without immobilizing them
If you study neurodegenerative diseases (ND), you already know they are one of the most challenging — and fascinating — types of diseases to study. With protein aggregation being a hallmark of ND,...
Phosphorylation of human aquaporin 2 (AQP2) allosterically controls its interaction with the lysosomal trafficking protein LIP5
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody
Structure of DtpA from E. coli in complex with Valganciclovir provides insights into drug binding of human PepT1